FMS - Today's Research Reports on Stocks to Watch: Fresenius Medical Care and Oragenics
NEW YORK, NY / ACCESSWIRE / October 18, 2018 / Oragenics was gaining on Wednesday after announcing it has received clearance to enroll patients into a Phase 2 clinical trial. Shares of Fresenius Medical Care were deep in the red as traders digested the company’s slashed guidance for the third quarter.
RDI Initiates Coverage on:
Fresenius Medical Care AG & Co. KGaA
https://www.rdinvesting.com/report/?ticker=FMS
Oragenics, Inc.
https://www.rdinvesting.com/report/?ticker=OGEN
Fresenius Medical Care AG & Co. KGaA shares closed down nearly 17% on about 1.1 million shares traded yesterday. The stock hit a new low of $40.86 after the company issued dismal guidance in its preliminary release of its third quarter financial results. The provider of dialysis products has slashed its targets for 2018. Net income growth is now expected to be in a range of 11 to 12%, compared to a previous expectation of 13 to 15%. Revenue growth is now expected to be just 2% to 3% compared to the 5% to 7% range earlier. The company has cited many reasons for the cuts. Wall Street has been eagerly waiting for the company's $2 billion acquisition of NxStage Medical to complete. In July, the German dialysis giant announced that it has moved the merger deadline from August 7 to Nov. 5, but still expects to close the deal this year.
Access RDI’s Fresenius Medical Care AG & Co. KGaA Research Report at:
https://www.rdinvesting.com/report/?ticker=FMS
Oragenics, Inc. shares closed up 9.65% on Wednesday, with about 9.6 million shares traded. The company announced that it has received clearance to enroll patients that live in Belgium from the Belgian Health Authority, The Federal Agency for Medicines and Health Products (FAMHP), into its Phase 2 clinical trial of AG013. AG013 is a live biotherapeutic product for the potential prevention and treatment of OM. “Enrolling patients outside of the United States provides an expansive patient base from which to draw for our trial of AG013, allowing us to more rapidly reach our goal of enrolling between 160-180 evaluable patients,” stated Alan Joslyn, Ph.D., president and CEO of Oragenics, Inc. He added, “The combination of the expanded number of clinical sites in the United States and Europe along with recent warrant exercises generating proceeds of approximately $9.5 million, should enhance our ability to complete the clinical study in 2019.”
Access RDI’s Oragenics, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=OGEN
Our Actionable Research on Fresenius Medical Care AG & Co. KGaA (NYSE: FMS) and Oragenics, Inc. (NYSE: OGEN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.SOURCE: RDInvesting.com